Efficacy of an antagonistic Anti-CD40 monoclonal antibody, HCD122 (CHIR-12.12), in preclinical models of human Non-Hodgkin's lymphoma and Hodgkin's disease.

被引：1
|
作者：
Long, Li
Patawaran, Montesa
Tong, Xia
Kantak, Seema
Aukerman, Sharon L.
Pryer, Nancy
Luqman, Mohammad
机构：
[1] Novartis Inst Biomed Res, Emeryville, CA USA
[2] LLC, XOMA US, Berkeley, CA USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.230.230
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
230
引用
收藏
页码：72A / 72A
页数：1
相关论文
共 50 条
  • [1] A fully human anti-CD40 antagonistic antibody, CHIR-12.12, inhibit the proliferation of human B cell non-Hodgkin's lymphoma
    Weng, WK
    Tong, X
    BLOOD, 2004, 104 (11) : 896A - 896A
  • [2] A phase I dose escalation study of a fully human, antagonist Anti-CD40 antibody, HCD122 (formerly CHIR-12.12) in patients with relapsed and refractory multiple myeloma.
    Bensinger, William
    Jagannath, Sundar
    Becker, Pamela S.
    Anderson, Kenneth C.
    Stadtmauer, Edward A.
    Aukerman, Lea
    Fox, Judith
    Girish, Sandhva
    Bilic, Sanela
    Guzy, Serge
    Solinger, Alan
    Dort, Sherri
    Wang, Yongyu
    Hurst, Deborah
    BLOOD, 2006, 108 (11) : 1021A - 1021A
  • [3] Preclinical Analysis of the Combined Activity of SGN-40, Anti-CD40 Monoclonal Antibody, with Rituximab in Non-Hodgkin Lymphoma
    Lewis, Timothy S.
    McCormick, Renee S.
    McEarchern, Julie A.
    Kissler, Kim
    Stone, Ivan J.
    Gerber, Hans-Peter
    Drachman, Jonathan G.
    Grewal, Iqbal
    Law, Che-Leung
    BLOOD, 2008, 112 (11) : 561 - 562
  • [4] Human anti-CD40 antagonistic antibodies, inhibit the proliferation of human B cell non-Hodgkin's lymphoma.
    Weng, WK
    Wang, CY
    Chu, KT
    Levy, R
    BLOOD, 2001, 98 (11) : 466A - 466A
  • [5] Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma
    Advani, Ranjana
    Forero-Torres, Andres
    Furman, Richard R.
    Rosenblatt, Joseph D.
    Younes, Anas
    Ren, Hong
    Harrop, Kate
    Whiting, Nancy
    Drachman, Jonathan G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) : 4371 - 4377
  • [6] The humanized anti-CD40 monoclonal antibody, SGN-40, signals apoptosis in non-Hodgkin's lymphoma by dual mechanisms.
    McCormick, Renee S.
    Lewis, Timothy S.
    Miyamoto, Jamie
    Sutherland, May S. K.
    Drachman, Jonathan G.
    Grewal, Iqbal S.
    Law, Che-Leung
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3451S - 3452S
  • [7] Human antagonistic anti-CD40 antibody, CHIR-12.12, inhibits CD40-mediated survival of chronic lymphocytic leukemia B cells leading to cellular apoptosis
    Cherukuri, A
    Kadel, E
    Lee, SH
    Goldbeck, C
    Heise, C
    Luqman, M
    Aukerman, SL
    Aziz, N
    O'Brien, S
    Wierda, WG
    Jallal, B
    BLOOD, 2005, 106 (11) : 832A - 832A
  • [8] Anti-CD20 monoclonal antibody therapy for non-Hodgkin's lymphoma
    White, CA
    Weaver, R
    Royston, I
    MINERVA BIOTECNOLOGICA, 1998, 10 (03) : 108 - 116
  • [9] Pharmaco kinetics and pharmacodynamics from a first-in-human phase 1 dose escalation study with antagonist anti-CD40 antibody, HCD122 (formerly CHIR-12.12), in patients with relapsed and refractory chronic lymphocytic leukemia.
    Byrd, John C.
    Flinn, Ian W.
    Khan, Khuda D.
    Kipps, Thomas J.
    Aukerman, Lea
    Fox, Judith
    Girish, Sandhya
    Guzy, Serge
    Bilic, Sanela
    Solinger, Alan
    Dort, Sherri
    Wang, Yongyu
    Hurst, Deborah
    O'Brien, Susan
    BLOOD, 2006, 108 (11) : 803A - 803A
  • [10] hCD122, an antagonist human Anti-CD40 monoclonal antibody, enhances efficacy of CHOP in tumor xenograft model of human diffuse large B-Cell lymphoma.
    Luqman, Mohammad
    Hsu, Ssucheng J.
    Ericson, Matthew
    Klabunde, Sha
    Kantak, Seema
    BLOOD, 2007, 110 (11) : 162A - 162A
12345